MX2019007555A - Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. - Google Patents

Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.

Info

Publication number
MX2019007555A
MX2019007555A MX2019007555A MX2019007555A MX2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A MX 2019007555 A MX2019007555 A MX 2019007555A
Authority
MX
Mexico
Prior art keywords
treat
gestational diabetes
diabetes mellitus
lactic acid
acid bacteria
Prior art date
Application number
MX2019007555A
Other languages
English (en)
Inventor
Lee Wickens Kristin
Original Assignee
Univ Of Otago
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Of Otago filed Critical Univ Of Otago
Publication of MX2019007555A publication Critical patent/MX2019007555A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/328—Foods, ingredients or supplements having a functional effect on health having effect on glycaemic control and diabetes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Dairy Products (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona métodos para tratar o prevenir la diabetes gestacional mediante la administración de lactobacillus rhamnosus HNO01 o derivados de esta, además de los usos, las composiciones y los medicamentos .que comprenden lactobacillus rhamnosus HNO01 o derivados de esta para tratar o prevenir la diabetes mellitus gestacional.
MX2019007555A 2016-12-22 2017-06-02 Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional. MX2019007555A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ72791416 2016-12-22
PCT/IB2017/053262 WO2018115985A1 (en) 2016-12-22 2017-06-02 Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus

Publications (1)

Publication Number Publication Date
MX2019007555A true MX2019007555A (es) 2020-01-30

Family

ID=62624701

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019007555A MX2019007555A (es) 2016-12-22 2017-06-02 Uso de bacterias de acido láctico para tratar o prevenir la diabetes mellitus gestacional.

Country Status (15)

Country Link
US (2) US11395839B2 (es)
EP (1) EP3558330B1 (es)
JP (1) JP7092380B2 (es)
KR (1) KR102513639B1 (es)
CN (1) CN110290795A (es)
AU (1) AU2017380603B2 (es)
BR (1) BR112019012965A2 (es)
CA (1) CA3047920C (es)
DK (1) DK3558330T3 (es)
MX (1) MX2019007555A (es)
MY (1) MY197917A (es)
NZ (1) NZ754706A (es)
PH (1) PH12019501439A1 (es)
RU (1) RU2769312C2 (es)
WO (1) WO2018115985A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117015309A (zh) * 2020-12-22 2023-11-07 方塔拉合作集团有限公司 乳酸杆菌用于抑制产甲烷菌生长或减少甲烷排放的用途
CN114990004B (zh) * 2022-04-19 2023-09-15 尚品健康科技(青岛)有限公司 一种分泌型免疫球蛋白a包裹态罗伊氏乳杆菌及防治妊娠糖尿病的应用
CN116694537B (zh) * 2023-07-28 2023-10-31 善恩康生物科技（苏州）有限公司 鼠李糖乳酪杆菌及其在制备治疗2型糖尿病产品中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0909170A4 (en) 1996-07-01 2000-02-09 Sepracor Inc METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERIC ENRICHED (S) -TRIDIHEXETHYL
DE69841826D1 (de) 1997-08-21 2010-09-23 New Zealand Dairy Board Immunitätsteigernde milchsäurebakterien
US20030191193A1 (en) 2002-04-03 2003-10-09 Jillian Cornish Lactoferrin
AU2006300009A1 (en) 2005-10-14 2007-04-19 Auckland Uniservices Limited Use of lactoferrin fragments and hydrolysates
AR060029A1 (es) 2006-03-02 2008-05-21 Unistraw Patent Holdings Ltd Pajilla para beber adaptada para acondicionar progresivamente un ingrediente activo y metodo de fabricar dicha pajilla
TW200841847A (en) 2006-11-06 2008-11-01 Unistraw Patent Holdings Ltd Functional filter for drinking straw
EP2011506A1 (en) * 2007-07-05 2009-01-07 Nestec S.A. Supplementation of maternal diet
US20110189149A1 (en) * 2008-06-20 2011-08-04 Remy Burcelin New Uses of Lactic Acid Bacteria and Bifidobacteria
US9737575B2 (en) * 2008-11-28 2017-08-22 University Of Otago Use of lactic acid bacteria to treat or prevent eczema
DK2525811T4 (en) * 2010-01-19 2019-04-08 Abbott Lab COMPOSITION, INCLUDING LACTOBACILLUS RHAMNOSUS HN001 AND PREBIOTICS FOR USE IN TREATMENT OF ALLERGIC LUNG DISEASE
CN107690332A (zh) 2015-06-11 2018-02-13 雀巢产品技术援助有限公司 膳食补充剂

Also Published As

Publication number Publication date
MY197917A (en) 2023-07-25
RU2769312C2 (ru) 2022-03-30
JP2020502247A (ja) 2020-01-23
AU2017380603B2 (en) 2022-02-03
AU2017380603A1 (en) 2019-07-11
EP3558330A4 (en) 2020-07-08
CN110290795A (zh) 2019-09-27
KR102513639B1 (ko) 2023-03-23
DK3558330T3 (da) 2022-11-07
PH12019501439A1 (en) 2020-02-24
JP7092380B2 (ja) 2022-06-28
EP3558330B1 (en) 2022-09-21
WO2018115985A1 (en) 2018-06-28
US11395839B2 (en) 2022-07-26
CA3047920C (en) 2022-07-19
KR20190107032A (ko) 2019-09-18
US20220387527A1 (en) 2022-12-08
US20200093873A1 (en) 2020-03-26
RU2019122811A3 (es) 2021-01-25
RU2019122811A (ru) 2021-01-25
CA3047920A1 (en) 2018-06-28
BR112019012965A2 (pt) 2019-11-26
NZ754706A (en) 2022-09-30
EP3558330A1 (en) 2019-10-30

Similar Documents

Publication Publication Date Title
PH12019502725A1 (en) Use of lactic acid bacteria to treat or prevent at least one of postnatal depression and postnatal anxiety
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019009132A (es) Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
AU2015205914B2 (en) 1,6- diazabicyclo [3,2,1] octan- 7- one derivatives and their use in the treatment of bacterial infections
MX340533B (es) Derivados de 1,6- diazabiciclo [3,2,1] octan-7-ona y su uso en el tratamiento de infecciones bacterianas.
MX2018004616A (es) Cosmetica qie tiene bacterias probioticas.
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
ZA201805358B (en) 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12016501988A1 (en) Antibacterial compounds
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
NZ745185A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2015005733A (es) Compuestos triciclicos para usarse en el tratamiento y/o control de obesidad.
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
JP2016003187A5 (es)
NZ784118A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.